Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission...
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission...
1. The use of fecal microbiota, live-jslm (RBL; REBYOTA®) in the prevention of recurrent Clostridioides difficile infection (rCDI) in patients...
1. In this cohort study of offspring born to mothers at risk for preterm delivery or diagnosed with an autoimmune...
1. The use of electrically heated mittens for 6 weeks was not associated with improved physical hand function in patients...
1. In this observational cohort study of patients with systemic lupus erythematosus, the current use of hydroxychloroquine as a treatment...
1. Low muscle strength, obesity, and sarcopenic obesity were associated with a greater risk of incident symptomatic knee osteoarthritis (OA)...
1. In this randomized controlled trial, once-weekly semaglutide led to significant weight loss compared to placebo over 68 weeks in...
1. BMD may differ on paretic and nonparetic sides in stroke patients with a history of falling and balance deficits...
1. The use of rituximab, abatacept and Janus kinase inhibitors (JAKis) in individuals with rheumatoid arthritis (RA) was associated with...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.